Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Commercial Insight - Multiple Sclerosis Continued growth makes the MS market a highly attractive investment (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 27/06/2007
- Report Title: Commercial Insight - Multiple Sclerosis Continued growth makes the MS market a highly attractive investment
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 114
Introduction
The dynamic MS market continues to grow unabated; seven major market revenues increased 14.7% from 2005 to $4.6 billion in 2006. Growth is driven by the highly successful beta-interferon brands, Teva's Copaxone (glatiramer acetate), and the recent relaunch of Tysabri; the first launch of a new MS treatment for six years.
Scope
This report focuses on the leading disease-modifying therapies used to treat MS, with seven major market (7MM) sales and volume forecasts to 2016
Assessment of current and future opportunities and threats in the MS market across the 7MMs
Future market events that are expected to affect drug revenues are discussed and quantified for each of the 7MMs
Lifecycle management case studies show how previously successful strategies should be applied in the current and future MS market
Highlights
Despite the comparatively large MS population, the UK only accounted for 1.1% of the 7MM total in 2006. The report believes the UK has potential to be a much more profitable and attractive MS market. If treatment rates were on par with Germany, the UK market could have been worth $293m in 2006almost six times higher than the actual value.
In order to successfully position a new drug class in the market, future market players must have a clear and focused marketing strategy. With Copaxonelaunched in 1997Teva has set the benchmark, and by utilizing similar tactics, future MS players can successfully position novel therapies in the market.
There remains a large opportunity for current and future players to cement and develop their positions in the MS market. To ensure continued revenue and to minimize franchise risk companies can follow Biogen Idec's strategy to market two or more products and show commitment to the MS community through long-term franchise investment.
Reasons to Purchase
Assess the impact of events such as patent expiries and new product launches on the sales of key marketed brands
Quantify the future size of the MS market, in terms of volume and value, in each of the 7MM
Identify key lifecycle management strategies that can ensure growth in the competitive MS market
The dynamic MS market continues to grow unabated; seven major market revenues increased 14.7% from 2005 to $4.6 billion in 2006. Growth is driven by the highly successful beta-interferon brands, Teva's Copaxone (glatiramer acetate), and the recent relaunch of Tysabri; the first launch of a new MS treatment for six years.
Scope
This report focuses on the leading disease-modifying therapies used to treat MS, with seven major market (7MM) sales and volume forecasts to 2016
Assessment of current and future opportunities and threats in the MS market across the 7MMs
Future market events that are expected to affect drug revenues are discussed and quantified for each of the 7MMs
Lifecycle management case studies show how previously successful strategies should be applied in the current and future MS market
Highlights
Despite the comparatively large MS population, the UK only accounted for 1.1% of the 7MM total in 2006. The report believes the UK has potential to be a much more profitable and attractive MS market. If treatment rates were on par with Germany, the UK market could have been worth $293m in 2006almost six times higher than the actual value.
In order to successfully position a new drug class in the market, future market players must have a clear and focused marketing strategy. With Copaxonelaunched in 1997Teva has set the benchmark, and by utilizing similar tactics, future MS players can successfully position novel therapies in the market.
There remains a large opportunity for current and future players to cement and develop their positions in the MS market. To ensure continued revenue and to minimize franchise risk companies can follow Biogen Idec's strategy to market two or more products and show commitment to the MS community through long-term franchise investment.
Reasons to Purchase
Assess the impact of events such as patent expiries and new product launches on the sales of key marketed brands
Quantify the future size of the MS market, in terms of volume and value, in each of the 7MM
Identify key lifecycle management strategies that can ensure growth in the competitive MS market
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
